Acute Efficacy and 6 Months Follow up After Electroconvulsive Therapy

Haukeland University Hospital600 enrolled

Overview

The overall aim of the current project is to assess the acute and long term outcome of ECT (both patient and clinician rated) in a non-selected patient cohort from ordinary clinical activity, and to seek out factors predicting response and remission, side effects and relapse.

Patients reffered to electroconvulsive ECT are (after written consent) enroled in a research registry. Based on (clinician and patient rated) measures of depressive symptoms and overall cognitive function, the short and long-term (6 months) efficacy of ECT will be described, and factors predicting response and relapse identified. The duration of possible cognitive impairment and factors predicting cognitive outcome will be examined.

Study Type

OBSERVATIONAL

Enrollment

600

Conditions

Depressive Disorder

Interventions

electroconvulsive therapyOTHER

electroconvulsive therapy

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients treated with ECT for major depression (F31.3-5, F32, F33) at Haukeland University Hospital or Stavanger University Hospital after 2013, * written consent to enrolment into the Regional Register for neurostimulation. Exclusion Criteria: * ECT performed on other indications than major depression. * No consent to the register.

Locations (2)

Haukeland University Hospital

Bergen, Norway

RECRUITING

Stavanger University Hospital

Stavanger, Norway

RECRUITING

Outcomes

Primary Outcomes

Change of Montgomery and Åsberg Depression Rating Scale (MADRS) score from pretreatment at posttreatment; MADRS range 0 - 60, with higher scores indicating more severe depression)

depressive symptoms

Time frame: up to 8 weeks

Change of Mini Mental State Examination (MMSE-NR) score from pretreatment at posttreatment; MMS-E range 0-30 with lower scores indicating more severe cognitive impairment

overall cognitive function

Time frame: up to 8 weeks

Change of Beck depression inventory (BDI) score from pretreatment at posttreatment; BDI range 0-63, with higher scores indicating more severe depression

depressive symptoms, patient rated

Time frame: up to 8 weeks

Change of Everyday Memory Questionnaire (EMQ) score from pretreatment at posttreatment with higher scores indicating more severe impairment

overall subjective cognitive function, patient rated

Time frame: up to 8 weeks

Secondary Outcomes

Change of Patient rated improvement (PGI) score from pretreatment at posttreatment

Likert scale

Time frame: up to 8 weeks

Change of Clinical Global Impression (CGI) score from pretreatment at posttreatment

Likert scale

Time frame: up to 8 weeks

Change of Subjective cognitive function score from pretreatment at posttreatment

Likert scale

Time frame: up to 8 weeks

Central Contacts

Ute Kessler, PhD

CONTACT

ute.kessler@helse-bergen.no

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.